Organic Cosolvent-Free Antibody–Drug Conjugation Enabled by Hydrophilic Linker–Payloads
- 1Exelixis, Inc. , 1851 Harbor Bay Parkway , , ,
Abstract
Bioconjugation of linker–payloads (LPs) to antibodies has historically relied on organic cosolvents or surfactants to overcome the poor aqueous solubility of cytotoxic payloads─an assumption that has remained largely unquestioned in antibody–drug conjugate (ADC) manufacturing. Here, we systematically re-evaluate this paradigm by characterizing the aqueous solubility of 13 representative LPs at operationally relevant concentrations (5–50 mM) across water and acidic buffers. Classical hydrophobic LPs, including vedotin, mafodotin, and deruxtecan, were confirmed to be insoluble under all aqueous conditions tested, validating their established dependence on cosolvents. However, LPs incorporating hydrophilic elements, such as PEG chains or ionizable groups, dissolved readily in water at concentrations sufficient for bioconjugation. Most notably, the linker–payload corresponding to sacituzumab govitecan (CL2A-SN-38) achieved concentrations of at least 50 mM in pure water, and two different conjugation reactions were successfully executed in fully aqueous buffered media without any organic solvents or surfactants. Physicochemical analysis revealed that solubility is not governed solely by global hydrophobicity (A log P) but is codetermined by PEG length, charge distribution, pH-dependent ionization, and the continuity of hydrophobic surface topology. Conjugation under fully aqueous conditions yielded ADCs with average DAR values of 1.6–1.9 under target-DAR2 conditions and 6.1–7.0 under target-DAR8 conditions, with minimal aggregation and physicochemical properties comparable to those produced via conventional cosolvent-based workflows. These findings demonstrate that rational hydrophilicity-driven LP design enables cosolvent-free conjugation, thereby simplifying ADC manufacturing, eliminating flammability hazards, removing residual solvent testing requirements, and reducing regulatory complexity.
Related
- Antibody-drug conjugate combination therapy targeting LGR5 and MET with different payloads enhances efficacy in preclinical colorectal cancer models
- Anti-PD-L1 antibody-coated metal-organic framework for targeted PTPN2 Inhibitor delivery and enhanced immunotherapy of head and neck squamous cell carcinoma
- Enhancing Skin Penetration of a Hydrophilic, Large Molecular Weight Compound Using a Nanoparticle-in-Oil Dispersion
- Characterization of Time-Dependent Dissolution of Hydrophilic PTCA Catheter Coating Particles Using Dynamic Image Analysis
- Structure-Dependent Effects of Lipid Conjugation on Cytosolic Accumulation in Escherichia coli and Mammalian Cells
BibTeX
@article{matsuda2026organic,
title = {{Organic Cosolvent-Free Antibody–Drug Conjugation Enabled by Hydrophilic Linker–Payloads}},
author = {Yutaka Matsuda and Hengqin Cheng and John Hartung and Ian Schwartz and Hui Li and Jenny R. Chang and Samantha S. Watson and Rajiv Mahajan and Brian A. Mendelsohn and Michael J. Martinelli},
journal = {ACS Omega},
year = {2026},
month = oct,
doi = {10.1021/acsomega.6c01543},
url = {https://pubs.acs.org/acsodf/article/11/41/62482/5448074/Organic-Cosolvent-Free-Antibody-Drug-Conjugation},
note = {CC BY-NC-ND 4.0},
}
RIS
TY - JOUR
TI - Organic Cosolvent-Free Antibody–Drug Conjugation Enabled by Hydrophilic Linker–Payloads
AU - Yutaka Matsuda
AU - Hengqin Cheng
AU - John Hartung
AU - Ian Schwartz
AU - Hui Li
AU - Jenny R. Chang
AU - Samantha S. Watson
AU - Rajiv Mahajan
AU - Brian A. Mendelsohn
AU - Michael J. Martinelli
PY - 2026
DA - 2026/10/09
JO - ACS Omega
DO - 10.1021/acsomega.6c01543
UR - https://pubs.acs.org/acsodf/article/11/41/62482/5448074/Organic-Cosolvent-Free-Antibody-Drug-Conjugation
AB - Bioconjugation of linker–payloads (LPs) to antibodies has historically relied on organic cosolvents or surfactants to overcome the poor aqueous solubility of cytotoxic payloads─an assumption that has remained largely unquestioned in antibody–drug conjugate (ADC) manufacturing. Here, we systematically re-evaluate this paradigm by characterizing the aqueous solubility of 13 representative LPs at operationally relevant concentrations (5–50 mM) across water and acidic buffers. Classical hydrophobic LPs, including vedotin, mafodotin, and deruxtecan, were confirmed to be insoluble under all aqueous conditions tested, validating their established dependence on cosolvents. However, LPs incorporating hydrophilic elements, such as PEG chains or ionizable groups, dissolved readily in water at concentrations sufficient for bioconjugation. Most notably, the linker–payload corresponding to sacituzumab govitecan (CL2A-SN-38) achieved concentrations of at least 50 mM in pure water, and two different conjugation reactions were successfully executed in fully aqueous buffered media without any organic solvents or surfactants. Physicochemical analysis revealed that solubility is not governed solely by global hydrophobicity (A log P) but is codetermined by PEG length, charge distribution, pH-dependent ionization, and the continuity of hydrophobic surface topology. Conjugation under fully aqueous conditions yielded ADCs with average DAR values of 1.6–1.9 under target-DAR2 conditions and 6.1–7.0 under target-DAR8 conditions, with minimal aggregation and physicochemical properties comparable to those produced via conventional cosolvent-based workflows. These findings demonstrate that rational hydrophilicity-driven LP design enables cosolvent-free conjugation, thereby simplifying ADC manufacturing, eliminating flammability hazards, removing residual solvent testing requirements, and reducing regulatory complexity.
SN - 2470-1343
ER -